The USA Gave Way to Studies in the Sphere of Stem cells

Obama has realized a rapid change of the course in comparison to the tight policy of Bush in the sphere of stem cells, as La Republica reports.

Some days ago National Institution of Health (NIH) authorized a private investment of the studies on 13 lines of stem cells (from each embryo it’s possible to sort out a separate line of stem cells, that is a family of cells which can be reproduce in vitro). Soon the researches will be carried out on 200 new lines. In Italy, for example, the creation of new cells is prohibited. Just some labs are working with embryo cells imported from abroad.

“The scene is starting to change. It’s just the first step in the line of new steps. Scientific society will get an opportunity to estimate the scale of the studies on stem cells”, - says Francis Collins, one of the leading genetics of world level and strong Christian. Scientists have already got a proposal to place the information about their projects in the Internet. Besides, the investment of 21 million dollars is ready. Stem cells are the 100% material for embryos; they can be divided to infinity and turn into any types of tissues. Manipulating those scientists try to “repair” the tissues damaged as a result of a great number of diseases, from spinal cord traumas to diabetes, from heart attack to Alzheimer's disease.

SOURCE: www.wbahealth.com

New Preparation for Chronic Pain Treatment

Biotechnological company Nutra Pharma announced the production of a new generic for chronic pain treatment Nyloxin OTC.

Nyloxin OTC is produced in the form of spray and is aimed at the treatment of chronic moderate pain syndrome among patients with MC and other neurological diseases. The preparation on the basis of cobra venom doesn’t influence opioid receptors and doesn’t cause any sedation and other side effects characteristic for other pain-killers. At the same time it possesses high anti-anginal effectiveness.

SOURCE: www.wbahealth.com

1 Feb, 2010

FDA Proves Seroquel XR as Additional Therapy

On December 4th Food and Drug Administration (FDA) proved Seroquel XR (Quetiapine, “AstraZeneca”), which should be used once in 24 hours as additional therapy to antidepressant treatment among adults with serious depressive dysfunctions, “The Guardian” reports.

At the same time FDA send to the company a Complete Response Letter in which they inquired some additional information about the preparation as monotherapy and supporting monotherapy

“AstraZeneca” note that the company will consider the contents of the letter, and after that the discussion of this question with the American regulatory organ will be continued.

SOURCE: www.wbahealth.com

27 Dec, 2009